XFOR News and Press, X4 Pharmaceuticals Inc.

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday...

2026-03-03 10:04:28 ET Summary After years of volatility and a brutal post-COVID correction, biotech investors have understandably become more selective. In the current climate, investors are looking for companies with funded clinical trials, tangible product pipelines, and balance ...

- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency’...

2026-02-16 17:57:36 ET X4 Pharmaceuticals, Inc. (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 12:30 PM EST... Read the full article on Seeking Alpha For further details see: X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securit...

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12...

BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026, the company issued inducement awards to new employees under the X4 Pharmac...

2025-12-01 09:09:48 ET ... Read the full article on Seeking Alpha For further details see: X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conferen...

2025-11-05 12:31:54 ET More on X4 Pharmaceuticals X4 Pharmaceuticals drops 5%, prices $135M equity X4 Pharmaceuticals announces proposed underwritten public offering Seeking Alpha’s Quant Rating on X4 Pharmaceuticals Historical earnings data for X4 Pha...

Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings Successful completion of two financial transactions totaling $240.3M; cash run...